Oncology News | pharmaphorum

News

FDA delays review of GSK’s momelotinib for myelofibrosis

GSK won’t be hearing from the FDA this month about its marketing application for momelotinib as a treatment for myelofibrosis patients with anaemia after all.

News

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

Roche has claimed FDA approval for its CD20xCD3 bispecific antibody Columvi as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), setting up an

News

Biomarker for aggressive fibrotic tumours gets FDA backing

A blood test in development that may be able to predict whether a solid tumour will be particularly aggressive has been given the support of the FDA.

News

Kura files $100m offer after menin inhibitor results in AML...

The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the prog

News

Seagen says Adcetris/Opdivo combo aces lymphoma trial

Seagen’s Adcetris was trounced by Bristol-Myers Squibb’s Opdivo in a head-to-head trial in classical Hodgkin lymphoma (cHL) reported at ASCO – but there may be a way for t

News

J&J files Carvykti for earlier use in multiple myeloma

As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo

FDA delays review of GSK’s momelotinib for myelofibrosis

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

Biomarker for aggressive fibrotic tumours gets FDA backing

Kura files $100m offer after menin inhibitor results in AML...

Seagen says Adcetris/Opdivo combo aces lymphoma trial

J&J files Carvykti for earlier use in multiple myeloma

Boehringer transfers schizophrenia DTx selling rights to Cli...

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks